Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026EP EuropaceOpen Access

No significant difference in VT/VF-free survival was observed between ICMP and NIDCMP groups (p=0.27), though in the primary prophylaxis subgroup, ICMP patients received significantly more ICD therapy (15.1% vs. 10.5%, p=0.045).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The study aimed to compare long-term follow-up outcomes, time to ICD therapy, and clinical factors affecting this time in patients undergoing ICD implantation for ischemic versus nonischemic dilated cardiomyopathy.

Does the rate of ICD therapy and event-free survival differ between patients with ischemic versus nonischemic dilated cardiomyopathy?

Population

1127 patients aged ≥18 years undergoing ICD implantation

Comparison

Ischemic cardiomyopathy (n=686) vs nonischemic dilated cardiomyopathy (n=441)

Design

Single-center retrospective study

Follow-up

Mean 38.1 months

Authors

AYA YetkinHYH YorgunEKE B Kaya

Discussion

Loading...

Member takes

Overview

Similar VT/VF-free survival and appropriate shock rates in NIDCMP versus ICMP; leaves open etiology-specific programming to reduce inappropriate shocks.

Key Points

  • This study aims to compare long-term outcomes of ICD implantation between ischemic and nonischemic dilated cardiomyopathy patients and assess clinical factors influencing time to therapy.
  • Retrospective analysis of patients aged ≥18 years who underwent ICD implantation from January 2015 to July 2024.
  • Patients divided into ischemic cardiomyopathy (n=686) and nonischemic dilated cardiomyopathy (n=441) groups.
  • Analysis included time to ICD therapy, appropriate/inappropriate shock rates, and event-free survival.
  • ICD therapy was recorded in 23.4% of patients with ischemic cardiomyopathy and 20.6% with nonischemic dilated cardiomyopathy during follow-up (p=0.27).
  • In the primary prophylaxis group, ICD therapy occurred in 15.1% of ischemic and 10.5% of nonischemic patients (p=0.045).
  • Inappropriate shock rates were significantly higher in the nonischemic group (16.5%) than in the ischemic group (10.3%) (p<0.01).

Structured PICO

Does the rate of ICD therapy and event-free survival differ between patients with ischemic versus nonischemic dilated cardiomyopathy?

P
Population
1127 patients aged ≥18 years who underwent implantable cardioverter defibrillator (ICD) implantation between January 2015 and July 2024, including 686 with ischemic cardiomyopathy (ICMP) and 441 with nonischemic dilated cardiomyopathy (NIDCMP). Mean age 63 ± 14 years, 75.1% male.
I
Intervention
Implantable cardioverter defibrillator (ICD) implantation in patients with ischemic cardiomyopathy (ICMP)
C
Comparator
Implantable cardioverter defibrillator (ICD) implantation in patients with nonischemic dilated cardiomyopathy (NIDCMP)
O
Outcome
Time to ICD therapy including shocks or antitachycardia pacing for ventricular tachycardia (VT) and ventricular fibrillation (VF)hard clinical

While overall VT/VF-free survival is similar between ischemic and nonischemic cardiomyopathy patients with ICDs, nonischemic patients experience higher rates of inappropriate shocks.

Cite This Study

Yetkin et al. (2026) studied this question.

synapsesocial.com/papers/6a3f9785125782b61d8657e0https://doi.org/10.1093/europace/euag105.931
View Full Paper
Ask AI
Bookmark
Share